Physician profile
John Kuryan
NPI 1528294790
$18,067.22
in general payments reported to CMS, 2019-2025
28 companies · $6,572 in 2025
The $6,572 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2020: $513 · 2021: $1,357 · 2022: $1,945 · 2023: $3,684 · 2024: $2,850 · 2025: $6,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,196 · Food and Beverage: $4,595 · Travel and Lodging: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,195.50 |
| Food and Beverage | $4,594.56 |
| Travel and Lodging | $316.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,097.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $5,876.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,671.08 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,117.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $532.82 | 2019-2025 | Dupixent |
| Blueprint Medicines Corporation | $381.50 | 2023-2024 | Ayvakit |
| Optinose US, INC. | $348.56 | 2019-2025 | |
| Amgen INC. | $229.28 | 2022-2025 | Tezspire |
| Kaleo, INC. | $227.62 | 2019-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $221.67 | 2022-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $218.81 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Genentech USA, INC. | $193.34 | 2019-2024 | Xolair |
| Pfizer INC. | $180.14 | 2022-2025 | |
| Abbvie INC. | $164.76 | 2022-2023 | |
| Dermavant Sciences, INC. | $89.88 | 2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $83.35 | 2024 | |
| Hikma Pharmaceuticals USA | $66.73 | 2023-2024 | Ryaltris |
| Grifols USA, LLC | $59.44 | 2025 | Xembify |
| Alk-Abello, INC | $51.31 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $43.05 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $40.04 | 2020 | |
| Shire North American Group INC | $37.04 | 2019 | |
| Merck Sharp & Dohme LLC | $35.73 | 2019 | |
| Covis Pharma Gmbh | $28.72 | 2022 | |
| Octapharma USA, INC. | $22.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.60 | 2022 | |
| Aimmune Therapeutics, INC. | $14.10 | 2022 | |
| Bio Products Laboratory USA, INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kuryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.